ClinicalDevicesCardiac device infections are associated with a significant mortality risk
Introduction
In the past decades, evidence-based indications for the implantation of cardiac rhythm devices expanded rapidly, resulting in a large increase in the number of device implantations.1, 2, 3, 4, 5, 6 The incidence of complications, of which cardiac device infections (CDIs) are among the most important, also increased subsequently, and it has been reported that the increase in the incidence of CDI has outpaced the increase in implantation rates.7, 8, 9
Current annual CDI rates vary from ∼1% after the first device implant up to 7% after device replacements and/or upgrades.10, 11, 12
CDIs present with a broad range of symptoms, varying from local complaints at the generator pocket site to severe systemic manifestations, and are associated with substantial morbidity and mortality.13 In addition to this high morbidity and mortality, CDI is associated with significant costs, which have been estimated at $50,000 per patient.14
Despite several studies reporting on considerable mortality rates following CDI, no risk assessments were conducted. The extent to which patients with CDI are at increased risk of death as compared with those who remain free from this condition is therefore yet unknown. The objective of this study was to assess the incidence, pathogens, and prognostic importance of CDI in recipients of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy – defibrillator (CRT-D).
Section snippets
Patient selection
At our tertiary care facility (Leiden University Medical Center, Leiden, The Netherlands), data of all patients who receive an ICD or CRT-D are recorded in the departmental cardiology information system (EPD-Vision, Leiden University Medical Center, Leiden, The Netherlands). At baseline, information of the implant procedure and clinical characteristics is collected and all ICD/CRT-Ds are interrogated during regular follow-up. For the current study, all patients who received their initial ICD or
Patient population
Between January 2000 and September 2009, 2574 patients received their initial ICD or CRT-D. Of these, 98 (3.8%) patients were considered lost to follow-up. The remaining 2476 patients (79% men; mean age 62 ± 13 years) were included in this analysis. The majority of these patients received an ICD (59%) and had ischemic heart disease (64%). Table 1 summarizes their baseline characteristics.
CDI
During a median follow-up of 30 [14, 55] months, 64 of the 2476 patients (2.6%) underwent device and lead
Discussion
In our study, the cumulative incidence of CDI in a large cohort of recipients of ICD and CRT-D was 1.1% at 1 year and 2.6% at 3 years after the initial device implantation. Ninety-two percent of late-occurring CDIs (>4.5 years after the initial device implantation) were observed following generator replacement. Importantly, those with CDI had 1-year and 3-year cumulative mortality rates of 16.9% and 27.5%, respectively, following device explantation, reflecting a 2-fold increased risk of death
Conclusions
CDI is a condition that might have serious implications. The incidence of CDI is 2.6% 3 years after the initial device implantation. Furthermore, the annual incidence appears to increase from 4.5 years after the initial device implantation. CDI is associated with a 2.4-fold increased risk of mortality compared to patients in whom CDI does not occur, necessitating the development of effective preventive strategies.
References (24)
- et al.
Increasing rates of cardiac device infections among Medicare beneficiaries: 1990–1999
Am Heart J
(2004) - et al.
Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003
J Am Coll Cardiol
(2006) How to treat and identify device infections
Heart Rhythm
(2007)- et al.
Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections
J Am Coll Cardiol
(2007) - et al.
Pacemaker infections: a 10-year experience
Heart Lung Circ
(2007) - et al.
Longevity of implantable cardioverter-defibrillators, influencing factors, and comparison to industry-projected longevity
Heart Rhythm
(2009) - et al.
Cardiac implantable electronic device infections: presentation, management, and patient outcomes
Heart Rhythm
(2010) - et al.
Dual antiplatelet therapy and heparin “bridging” significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation
J Am Coll Cardiol
(2010) - et al.
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
N Engl J Med
(1996) - et al.
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction
N Engl J Med
(2002)
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
N Engl J Med
Cardiac resynchronization in chronic heart failure
N Engl J Med
Cited by (63)
Early Lead Extraction for Infected Implanted Cardiac Electronic Devices: JACC Review Topic of the Week
2023, Journal of the American College of CardiologyComplications and inappropriate shocks in pediatric patients receiving a subcutaneous implantable cardioverter defibrilator
2023, Revista Espanola de CardiologiaPredictors for mortality in patients admitted with suspected bacterial infections – A prospective long-term follow-up study
2022, American Journal of Emergency MedicineCitation Excerpt :Sohail et al. [47] likewise discovered that patients with cardiovascular implantable electronic device infections had increased device-dependent long-term mortality even after successful infection treatment. De Bie et al. [48] found that cardiac device infections were responsible for more than twofold increased mortality than patients who remained free from infection. Another study by Iordanou et al. [49] found a crude ICU mortality rate of 40% for the patients who acquired device-associated infections and 17.9% for patients who did not.
Defibrillator generator replacements in patients with left ventricular assist device support: The risks of hematoma and infection
2022, Journal of Heart and Lung TransplantationIncidence of lead erosion in a real-world cohort and a case of successful treatment with an antimicrobial mesh
2022, International Journal of CardiologyMalignancies masquerading as device pocket infections
2021, HeartRhythm Case Reports
Professor Schalij received research grants from Medtronic, Biotronik, and Boston Scientific.